Aniara | Shaping the Future with Innovative Solutions

Aniara Grant

2007 Coagulation Grant Winner

Aniara is happy to announce the winner of the 2007 Aniara grant in the amount of $5000.

Margaret Prechel Ph.D.
Dr. Margaret Prechel, Ph.D.
Departments of Pathology and Cardiovascular & Thoracic Surgery
Assistant Professor
Loyola University Medical Center
Maywood, Illinois USA

Dr. Margaret Prechel, Ph.D. is Assistant Professor in the Departments of Pathology and Cardiovascular & Thoracic Surgery at the Loyola University Medical Center in Maywood, Illinois. She joined the prominent Thrombosis and Hemostasis Research Group at Loyola in 1999.

In addition to teaching in the Stritch School of Medicine, Dr. Prechel is Supervisor of Loyola's Serotonin Release Assay Laboratory, a reference lab for diagnosis of Heparin-Induced Thrombocytopenia (HIT). Her research studies, conducted within the Cardiovascular Research Institute, focus on evaluating the effects of physiological variables, or of novel anticoagulant drugs on HIT antibody-mediated platelet activation.

Frequency of Heparin-Dependent Anti-Chemokine Antibodies  and their Cross-Reactivity in the Serotonin Release Assay for Diagnosis of Heparin-Induced Thrombocytopenia

Heparin-Induced Thrombocytopenia (HIT) is a potentially devastating side-effect of heparin (H) anticoagulant therapy, characterized by drop in platelet count and a paradoxically high risk for thrombotic complications. The primary HIT pathogen is an auto-antibody that forms in response to the altered conformation of platelet factor 4 (PF4) that occurs when this protein is bound to unfractionated heparin. Two types of laboratory tests are used to aid in the diagnosis of HIT; activations assays use donor platelets in vitro to look for activation in the presence of heparin and the test serum, and antigen tests are enzyme-linked immunosorbent assays (ELISAs) to detect immunoglobulins targeted to the antigenic PF4 neoepitopes. In many instances specimens test positive in the Serotonin Release Assay (SRA) of platelet activation, but negative in the H:PF4 antibody ELISA. Since heparin binds to many different chemokines, it is possible that other auto-antibodies are elicited during heparin anticoagulant therapy. The current project aims to evaluate the frequency of development of anti-chemokine antibodies in addition to those to H:PF4, and to determine if these antibodies cross-react in the SRA test for HIT diagnosis.


View Video



2010 - Leonardo Brandao, MD


2009 - Dr. Mirta Schattner, Ph.D.
2008 - Dr. Graciela Krikun, Ph.D.
2007 - Dr. Margaret Prechel, Ph.D.
2006 - Dr. A. Valance Washington, Ph.D.

Scientific Advisiors

Dr. Dorothy Adcock
Medical Director/Laboratory Director Colorado Coagulation Consultants, Inc, dba Esoterix Coagulation Denver, Colorado

Dr. Kenneth A. Bauer
Professor of Medicine, Harvard Medical School. His hospital positions include Chief, Hematology Section, VA Boston Healthcare System, and Director, Thrombosis Clinical Research, Beth Israel Deaconess Medical Center.

Dr. Charles S. Eby
Associate Director of Educational Programs, Division of Laboratory Medicine at Washington University Saint Louis, Member of Barnes-Jewish Hospital Credentialing and Health Information Management Committees.

Dr. Andreas Hillarp
Position as hospital chemist at the Department of Clinical Chemistry, University Hospital, Malmö, Sweden.

Dr. Mervyn A. Sahud, M.D., A.B.I. M.-Hem.
Medical Director Coagulation Department Quest Diagnostics Nichols Institute

Dr. Sam Schulman
Associate professor in Internal Medicine at Karolinska Institute and since September 2004 also professor in medicine at McMaster University.

Agneta Siegbahn, MD, Ph.D.
Professor in Clinical Coagulation Science Department of Medical Sciences, Clinical Chemistry Akademiska Hospital, Uppsala, Sweden

Jogin R. Wu, Ph.D.
Associate Clinical Professor of Pathology, Duke University Medical Center. Associate Director, Clinical Coagulation Laboratory, Duke University Health System.

This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.